PT1824988T - Mutagénese de fviii dirigida ao local - Google Patents

Mutagénese de fviii dirigida ao local

Info

Publication number
PT1824988T
PT1824988T PT58493925T PT05849392T PT1824988T PT 1824988 T PT1824988 T PT 1824988T PT 58493925 T PT58493925 T PT 58493925T PT 05849392 T PT05849392 T PT 05849392T PT 1824988 T PT1824988 T PT 1824988T
Authority
PT
Portugal
Prior art keywords
fviii
site
directed modification
modification
directed
Prior art date
Application number
PT58493925T
Other languages
English (en)
Portuguese (pt)
Inventor
Q Pan Clark
E Murphy John
Mei Baisong
S Strauss Jonathan
Tjandra Hendri
Chen Jianmin
Barnett Thomas
Tang Liang
Wang Deqian
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1824988(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PT1824988T publication Critical patent/PT1824988T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
PT58493925T 2004-11-12 2005-11-14 Mutagénese de fviii dirigida ao local PT1824988T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
PT1824988T true PT1824988T (pt) 2017-07-21

Family

ID=36337298

Family Applications (4)

Application Number Title Priority Date Filing Date
PT58493925T PT1824988T (pt) 2004-11-12 2005-11-14 Mutagénese de fviii dirigida ao local
PT161869011T PT3130601T (pt) 2004-11-12 2005-11-14 Modificação de fviii dirigida ao local
PT111533006T PT2363414T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio
PT111532974T PT2371856T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT161869011T PT3130601T (pt) 2004-11-12 2005-11-14 Modificação de fviii dirigida ao local
PT111533006T PT2363414T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio
PT111532974T PT2371856T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio

Country Status (32)

Country Link
US (4) US7632921B2 (enExample)
EP (9) EP3243834A1 (enExample)
JP (5) JP2008524117A (enExample)
KR (7) KR101243564B1 (enExample)
CN (6) CN103102406B (enExample)
AU (1) AU2005304622B2 (enExample)
BE (1) BE2019C523I2 (enExample)
BR (2) BR122016022033B8 (enExample)
CA (1) CA2586379C (enExample)
CY (3) CY1119292T1 (enExample)
DK (3) DK2371856T3 (enExample)
ES (4) ES2930143T3 (enExample)
FR (1) FR19C1031I2 (enExample)
HN (1) HN2007015683A (enExample)
HR (2) HRP20180481B1 (enExample)
HU (5) HUE060016T2 (enExample)
IL (3) IL182903A (enExample)
LT (5) LT2371856T (enExample)
LU (1) LUC00118I2 (enExample)
MA (1) MA29663B1 (enExample)
MX (3) MX2007005466A (enExample)
NL (1) NL300989I2 (enExample)
NO (3) NO345800B1 (enExample)
NZ (1) NZ555032A (enExample)
PH (2) PH12014500352B1 (enExample)
PL (3) PL2363414T3 (enExample)
PT (4) PT1824988T (enExample)
RU (1) RU2423380C2 (enExample)
SI (4) SI2371856T1 (enExample)
UA (1) UA95225C2 (enExample)
WO (1) WO2006053299A2 (enExample)
ZA (1) ZA200703696B (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
PL2363414T3 (pl) 2004-11-12 2022-09-05 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja FVIII
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
BRPI0712008A2 (pt) * 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag derivados e análogos de fix prolongados
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8173597B2 (en) * 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
AU2009219232B2 (en) * 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
KR20110022604A (ko) 2008-05-16 2011-03-07 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
BRPI0913374A2 (pt) * 2008-06-04 2015-11-24 Bayer Healthcare Llc muteínas fviii para tratamento de doença de von willebrand
ES2654336T3 (es) 2008-06-24 2018-02-13 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
LT2349342T (lt) * 2008-10-17 2018-10-10 Baxalta GmbH Modifikuoti kraujo faktoriai, apimantys nedidelį vandenyje tirpaus polimero kiekį
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
EP2368124A4 (en) * 2008-11-24 2012-09-19 Bayer Healthcare Llc METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
EP2398822B1 (en) * 2009-02-19 2013-01-02 Novo Nordisk A/S Modification of factor viii
EP2408800B1 (en) * 2009-03-20 2016-05-25 Hanmi Science Co., Ltd. Method for preparing a site-specific conjugate of a physiologically active polypeptide
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2459224B1 (en) 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
NZ601905A (en) * 2010-02-21 2014-09-26 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
KR20200067958A (ko) 2010-04-15 2020-06-12 코디악 사이언시스 인코포레이티드 고분자량 쌍성이온-함유 중합체
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2591101B1 (en) * 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
BR112013011041B1 (pt) * 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
US20130345403A1 (en) * 2010-12-16 2013-12-26 Novo Nordisk A/S Aqueous factor viii solution
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
US20120329127A1 (en) * 2011-05-27 2012-12-27 Baxter Healthcare S.A. Therapeutic proteins with increased half-life and methods of preparing same
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TWI764092B (zh) 2011-07-08 2022-05-11 美商百歐維拉提夫治療公司 因子viii嵌合及雜交多肽，及其使用方法
CN104093735B (zh) 2011-09-23 2018-07-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
KR20150132449A (ko) * 2013-03-15 2015-11-25 바이엘 헬스케어 엘엘씨 재조합 인자 viii 제제
PT2968477T (pt) 2013-03-15 2020-03-11 Bioverativ Therapeutics Inc Formulações de polipéptido de fator viii
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
AU2014339034A1 (en) * 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
DK3097118T3 (en) 2014-01-20 2018-11-05 Octapharma Ag PROCEDURE FOR MANUFACTURING FACTOR VIII WITH AN IMPROVED FVIII: C / FVIII: AG RELATIONSHIP
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
KR20160144429A (ko) 2014-04-10 2016-12-16 바이엘 헬쓰케어 엘엘씨 배합된 배지 분말 제형 및 세포 배양을 위한 액체 배지의 제조 방법
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
CN106659771B (zh) 2014-07-02 2021-09-24 康诺贝林伦瑙有限公司 修饰的von Willebrand因子
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
US10688157B2 (en) 2015-05-22 2020-06-23 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for treating hemophilia
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
KR20180098404A (ko) 2016-01-07 2018-09-03 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 폰 빌레브란트 인자
US10806774B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
WO2017222330A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
WO2018087267A1 (en) 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
ES2908008T3 (es) 2016-11-11 2022-04-27 CSL Behring Lengnau AG Polipéptidos truncados del Factor de von Willebrand para su administración extravascular en el tratamiento o profilaxis de un trastorno de la coagulación sanguínea
BR112019010034A2 (pt) 2016-11-16 2019-09-03 Bayer Healthcare Llc fator viii alvejado de hemácia e método de uso do mesmo
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
TW201831521A (zh) 2017-01-31 2018-09-01 美商生物化學醫療公司 因子ｉｘ融合蛋白以及其製備方法及使用方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
JP2021530437A (ja) 2018-05-18 2021-11-11 鄭州晟斯生物科技有限公司Zhengzhou Gensciences Inc 改良されたｆｖｉｉｉ融合タンパク質及びその応用
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
US20220403005A1 (en) * 2019-12-06 2022-12-22 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5733873A (en) 1992-10-02 1998-03-31 Pharmacia & Upjohn Ab Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
WO1997001197A1 (en) * 1995-06-21 1997-01-09 Motorola Inc. Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
RU2199347C2 (ru) * 1996-08-02 2003-02-27 Орто-Макнейл Фармасьютикал, Инк. Полипептиды, обладающие единственным ковалентно связанным n-концевым водорастворимым полимером
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CA2349468C (en) 1998-11-10 2013-07-09 Baxter Aktiengesellschaft Factor viii polypeptide having factor viii:c activity
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ES2373093T3 (es) * 1999-01-14 2012-01-31 Bolder Biotechnology, Inc. Métodos para preparar proteínas que contienen restos de cisteína libres.
EP1183354A2 (en) 1999-05-24 2002-03-06 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
AU2001292861A1 (en) 2000-09-19 2002-04-02 Emory University Modified factor VIII
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
CN100567487C (zh) * 2001-03-22 2009-12-09 诺沃挪第克健康护理股份公司 凝血因子vii衍生物
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
CA2461443C (en) 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2003087161A1 (en) 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
AU2003300139B2 (en) 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
KR101177340B1 (ko) 2003-01-06 2012-08-30 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
JP5539607B2 (ja) * 2003-02-26 2014-07-02 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー−ｖｉｉｉ因子部分結合体
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2525464A1 (en) 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
CA2510040C (en) 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
PL2363414T3 (pl) 2004-11-12 2022-09-05 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja FVIII
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
KR101243564B1 (ko) 2013-03-27
WO2006053299A2 (en) 2006-05-18
PL2363414T3 (pl) 2022-09-05
HK1182121A1 (en) 2013-11-22
ZA200703696B (en) 2008-08-27
LUC00118I2 (enExample) 2019-12-27
ES2821832T3 (es) 2021-04-27
EP3153181A1 (en) 2017-04-12
CN103214569B (zh) 2016-12-28
EP2371856B1 (en) 2022-05-18
EP2363414A3 (en) 2012-03-21
CN105753968A (zh) 2016-07-13
IL232540A (en) 2017-08-31
KR101468345B1 (ko) 2014-12-03
PH12014500352A1 (en) 2015-07-20
EP3323829A1 (en) 2018-05-23
US20160051633A1 (en) 2016-02-25
CN105148287A (zh) 2015-12-16
BR122016022033B1 (pt) 2021-03-02
EP3243833B1 (en) 2020-06-17
CN101124331B (zh) 2013-04-24
CY1123384T1 (el) 2021-12-31
PT3130601T (pt) 2020-10-01
CN103102406B (zh) 2015-05-27
KR101654011B1 (ko) 2016-09-05
EP2363414A2 (en) 2011-09-07
NO20072997L (no) 2007-06-27
LT2363414T (lt) 2022-10-25
JP2017105773A (ja) 2017-06-15
BRPI0517795B1 (pt) 2020-03-31
HN2007015683A (es) 2011-07-11
HUS1900026I1 (hu) 2022-04-28
PL2371856T3 (pl) 2022-08-22
IL232540A0 (en) 2014-06-30
EP3243833A1 (en) 2017-11-15
EP3323829B1 (en) 2020-07-15
CY2019024I2 (el) 2019-11-27
NO345800B1 (no) 2021-08-09
KR20140019489A (ko) 2014-02-14
MX350293B (es) 2017-09-04
EP1824988B1 (en) 2017-04-19
HUE060016T2 (hu) 2023-01-28
SI1824988T1 (sl) 2017-11-30
RU2423380C2 (ru) 2011-07-10
SI2371856T1 (sl) 2022-09-30
ES2633916T3 (es) 2017-09-26
ES2930143T3 (es) 2022-12-07
UA95225C2 (ru) 2011-07-25
HRP20180481A2 (hr) 2018-06-29
KR101904630B1 (ko) 2018-10-04
MX392760B (es) 2025-03-24
JP2017101028A (ja) 2017-06-08
PT2371856T (pt) 2022-08-12
BRPI0517795B8 (pt) 2021-05-25
CY2019024I1 (el) 2019-11-27
CN105148287B (zh) 2019-07-09
EP3130601A1 (en) 2017-02-15
CA2586379C (en) 2012-04-03
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
CN107082806A (zh) 2017-08-22
US7632921B2 (en) 2009-12-15
JP2015134780A (ja) 2015-07-27
RU2007121517A (ru) 2008-12-20
KR20140091618A (ko) 2014-07-21
KR101483917B1 (ko) 2015-01-16
DK2363414T3 (da) 2022-08-08
KR20120136413A (ko) 2012-12-18
EP2772500A1 (en) 2014-09-03
NZ555032A (en) 2010-02-26
FR19C1031I2 (fr) 2020-06-05
HK1218718A1 (zh) 2017-03-10
AU2005304622A1 (en) 2006-05-18
PT2363414T (pt) 2022-08-04
HRP20180481B1 (hr) 2022-02-18
HUE050542T2 (hu) 2020-12-28
US20060115876A1 (en) 2006-06-01
NO344606B1 (no) 2020-02-10
US9096656B2 (en) 2015-08-04
HUE033776T2 (en) 2018-01-29
JP2008524117A (ja) 2008-07-10
DK1824988T3 (en) 2017-08-07
JP6018238B2 (ja) 2016-11-02
EP1824988A2 (en) 2007-08-29
KR20130036780A (ko) 2013-04-12
EP2371856A3 (en) 2012-03-14
US9364520B2 (en) 2016-06-14
MX2007005466A (es) 2007-10-19
US20130274445A1 (en) 2013-10-17
PL1824988T3 (pl) 2018-01-31
HK1117875A1 (en) 2009-01-23
LT1824988T (lt) 2017-10-25
WO2006053299A3 (en) 2006-08-24
JP6109523B2 (ja) 2017-04-05
NL300989I1 (nl) 2019-05-22
LT2371856T (lt) 2022-08-25
BRPI0517795A8 (pt) 2018-12-26
EP2772500B1 (en) 2019-12-25
JP2013067621A (ja) 2013-04-18
EP3243834A1 (en) 2017-11-15
CN101124331A (zh) 2008-02-13
FR19C1031I1 (enExample) 2019-06-28
BE2019C523I2 (enExample) 2025-02-10
US20100081615A1 (en) 2010-04-01
KR20070110260A (ko) 2007-11-16
LT3130601T (lt) 2020-09-10
KR20160105928A (ko) 2016-09-07
PH12014500352B1 (en) 2019-09-25
BRPI0517795A (pt) 2008-10-21
CN103102406A (zh) 2013-05-15
IL182903A0 (en) 2007-08-19
HRP20070268A2 (en) 2007-09-30
NL300989I2 (nl) 2019-11-28
LUC00118I1 (enExample) 2019-05-13
SI3130601T1 (sl) 2020-11-30
AU2005304622B2 (en) 2012-03-29
JP6487895B2 (ja) 2019-03-20
JP6559642B2 (ja) 2019-08-14
HRP20070268B1 (hr) 2018-04-20
BR122016022033B8 (pt) 2021-05-25
CY1119292T1 (el) 2018-02-14
CA2586379A1 (en) 2006-05-18
LTPA2019509I1 (lt) 2019-08-26
MA29663B1 (fr) 2008-08-01
HUE059193T2 (hu) 2022-10-28
DK2371856T3 (en) 2022-08-08
PH12019501613A1 (en) 2020-09-14
EP1824988A4 (en) 2008-12-31
IL234433B (en) 2019-11-28
EP3130601B1 (en) 2020-07-15
NO20200044A1 (no) 2007-06-27
LTC1824988I2 (lt) 2021-02-25
CN103214569A (zh) 2013-07-24
IL182903A (en) 2014-09-30
EP2363414B1 (en) 2022-05-18
ES2930159T3 (es) 2022-12-07
EP2371856A2 (en) 2011-10-05
KR20180110192A (ko) 2018-10-08

Similar Documents

Publication Publication Date Title
IL234433B (en) Site-directed modification of factor viii
GB0426503D0 (en) Improved osteotome
IL183634A0 (en) Polymer-von willebrand factor-conjugates
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
EP1773871A4 (en) COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES
EP1785131A4 (en) EXTERNAL PREPARATION OF TYPE S / O
ZA200606315B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
AU300055S (en) Scrubber
PL1720633T3 (pl) Płuczka wieżowa gazu
GB0428026D0 (en) Infant aid
GB0517332D0 (en) Improved building components
GB2416051B (en) Selection of component
ZA200508325B (en) Manufacture of kerbstones
GB0421155D0 (en) Piece of mind plan
GB0415217D0 (en) Compounds and uses thereof
GB0412872D0 (en) Novel structures
PL369353A1 (pl) Zestaw elementów budowlanych
AU157294S (en) External cornice corner member
TWM275831U (en) Improved structure of cinerary urn
SI1835938T1 (sl) Konjugati polimera in von Willebrandovega faktorja
GB0415721D0 (en) Novel preparation
GB0402464D0 (en) Child walker